News | May 14, 2025
Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Investment demonstrates confidence in America’s commitment to science and innovation
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
Sharma brings a wealth of expertise in optimizing manufacturing processes for fermentation-based APIs and sterile injectables
Strengthening capabilities in Peptide Therapeutics and CDMO services
Asahi Kasei Life Science covers a broad range of bioprocess products and services
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
Subscribe To Our Newsletter & Stay Updated
